At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 13 enrolled
Drug / intervention
Rosuvastatin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I, Open-label, Fixed Sequence Crossover Study to Investigate the Effect of Coadministration of Sotorasib on the Pharmacokinetics of Rosuvastatin, a Breast Cancer Resistance Protein Substrate, in Healthy Subjects
In Brief
A Phase 1 clinical trial evaluating Rosuvastatin and Sotorasib for Healthy Participants. Completed, enrolled 13 participants across 1 site.
Detailed Summary
A study to determine the effect of sotorasib on the pharmacokinetics (PK) of rosuvastatin, and to assess the PK of rosuvastatin when administered alone, in healthy participants.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Participants
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20222023202420252026
Enrollment StartAug 2021
First PostedSep 2021
Primary CompletionOct 2021
TodayJul 2026
First PostedSep 16, 2021
Enrollment StartAug 20, 2021
Primary CompletionOct 10, 2021
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 4.8 years ago
Interventions
Rosuvastatindrug
Oral dose
Sotorasibdrug
Oral dose